Cooley

Mike Nelson

Partner



mnelson@cooley.com

Emerging Companies

Venture Capital

+1 720 566 4021

Life Sciences Medtech

Healthcare

пе

Colorado

Boston

Digital Health

Mike's practice focuses on advising emerging and growth-stage life sciences and deep tech companies, as well as the funds that invest in them, on matters relating to corporate finance, corporate governance, licensing and other intellectual property-based transactions, mergers and acquisitions, and public offerings.

Mike's representative matters include new deals for:

- Superluminal Medicines
- Navigator Medicines
- Clasp Therapeutics
- Adela
- Hyku
- CubicPV

Publications

- Co-author, "A Modeling Study of T-Type Ca2+ Channel Gating and Modulation by L-Cysteine in Rat Nociceptors," Biophysical Journal 98: 197 – 206, 2010
- Co-author, "Molecular Mechanisms of Subtype-Specific Inhibition of Neuronal T-Type Calcium Channels by Ascorbate," Journal of Neuroscience 27: 12577 – 1258, 2007
- Co-author, "Reducing Agents Sensitize C-Type Nociceptors by Relieving High-Affinity Zinc Inhibition of T-Type Calcium Channels," Journal of Neuroscience 27: 8250 – 8260, 2007
- Co-author, "Is There a Role for T-Type Calcium Channels in Peripheral and Central Pain Sensitization?"
 Molecular Neurobiology 34: 243 248, 2006
- Co-author, "The Role of T-Type Calcium Channels in Epilepsy and Pain," Current Pharmaceutical Design 12: 2189 – 2197, 2006
- Co-author, "The Endogenous Redox Agent L-Cysteine Induces T-Type Ca2+ Channel-Dependent Sensitization of a Novel Subpopulation of Rat Peripheral Nociceptors," Journal of Neuroscience 25: 8766 – 8775, 2005

Education

University of Denver Sturm College of Law JD, 2010

University of Virginia

PhD, 2007

Boston University

MS, 2002

Willamette University

BS, 2000

Admissions & Credentials

Colorado

Massachusetts

Memberships & Affiliations

American Bar Association (ABA)

Colorado Bar Association

Massachusetts Bar Association

American Association for the Advancement of Science

Society for Neuroscience